BOSTON, April 5, 2021: Morgan Lewis is bolstering its global life sciences team with the addition of partner Suzanne Filippi, who has almost two decades of experience in the biopharmaceutical and technology sectors, including strategic roles both in-house and in private practice. Suzanne has advised on complex corporate, capital markets, and strategic partnering transactions for life sciences companies across the United States and around the world. She is resident in the Boston office and arrives from the life sciences group at Hogan Lovells. Previously, she served in senior legal roles in the biopharmaceutical and technology industries.
“Suzanne’s sophisticated biotech in-house and law firm experience gives her the collaborative and business savvy edge our clients depend on when pursuing new strategic business opportunities,” said Firm Chair Jami McKeon. “Our global life sciences transactions team is reinforced by Suzanne’s arrival as we navigate clients around the globe through remaining COVID-related issues and the implications of the American Rescue Plan Act.”
Suzanne’s practice focuses on complex collaboration/licensing transactions, strategic alliances, clinical and commercial supply transactions, build-to-buy transactions, public and private mergers and acquisitions, venture capital, and joint ventures. She also provides practical guidance on general corporate matters such as securities compliance, corporate governance, executive compensation, and a range of other everyday business issues. In the life sciences industry, her guidance supports clients at every stage of the development cycle, from clinical to commercial. She also advises clients that are going public, considering exits, exploring partnership opportunities, experiencing the onset of a hypergrowth stage, and entering new markets, among other matters.
Steve Browne, leader of Morgan Lewis’s global corporate and business transactions practice, said, “We are thrilled to welcome Suzanne to our firm and to our Boston office. She is a strong deal lawyer with years of in-house M&A counsel and life sciences industry experience. Suzanne has an established track record of entrepreneurial client development in the highly competitive life sciences sector and is a fantastic fit for our market-leading life sciences emerging business and transactions team.”
Morgan Lewis’s global life sciences team serves the pharmaceutical, biotechnology, medical device, and related industries, as well as the entities that invest in them, such as venture capital and private equity funds. The team advises on a variety of issues including corporate transactions, initial public offerings, strategic alliances, regulatory issues, intellectual property matters, and litigation.
“In a time when life sciences companies are seeing a proliferation of complex licensing and collaboration transactions as well as sustained M&A activity, clients are seeking counsel such as Suzanne with her in-depth knowledge of the industry,” said Alan Leeds, leader of Morgan Lewis’s life sciences transactions practice and co-leader of the firm’s life sciences industry initiative. “Clients value her entrepreneurial approach and seasoned counsel on a vast range of issues that are critical to their businesses.”